Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 16/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20111271 | 0.87 | FEN1 (0.35) | — | |
| SCHEMBL20102486 | 0.86 | OPRL1 (0.39) | MEN1MAPK1KMT2ACYP2C9ALDH1A1 | |
| SCHEMBL20102477 | 0.85 | MEN1 (0.36) | MEN1MAPK1KMT2ACYP2C9ALDH1A1 | |
| SCHEMBL20102476 | 0.85 | CYP2C9 (0.36) | MEN1MAPK1KMT2ACYP2C9ALDH1A1 | |
| SCHEMBL20111677 | 0.85 | OPRL1 (0.31) | OPRL1 | |
| SCHEMBL20111335 | 0.84 | OPRL1 (0.31) | OPRL1 | |
| SCHEMBL20111329 | 0.84 | OPRL1 (0.40) | MEN1MAPK1KMT2ACYP2C9ALDH1A1 | |
| SCHEMBL20102395 | 0.83 | MEN1 (0.33) | MEN1MAPK1KMT2ACYP2C9ALDH1A1 | |
| SCHEMBL20102554 | 0.83 | MEN1 (0.33) | MEN1MAPK1KMT2ACYP2C9ALDH1A1 | |
| SCHEMBL20111308 | 0.83 | ALDH1A1 (0.36) | MEN1MAPK1KMT2ACYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | MEN1 2571/4885MAPK1 1115/4885KMT2A 2759/4885 |
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | YBX1, PIEZO1, C1S | MEN1 2571/4885MAPK1 1115/4885KMT2A 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.